Skip to main content
. 2024 May 2;27(6):109873. doi: 10.1016/j.isci.2024.109873

Figure 1.

Figure 1

Overview of the study and input data

(A) Schematic demonstration of interactions between mutational signatures, pathway alterations, and immune state.

(B) Number of samples in PCAWG across cancer types.

(C) Number of active mutational signatures in PCAWG across cancer types. Colors in (B) and (C) correspond to individual cancer types with >25 samples. See also Figure S1.